Do you have Neuroblastoma or Osteosarcoma that has either come back or did not get better with your last treatment? If so, you may be able to take part in a study that will modify your own immune cells to see if it may treat your cancer.

Researchers are studying different doses of a therapy (CD19 CAR T-cells) to find the dose that is both the most effective and the safest for patients with relapsed or refractory B-cell lymphoma.

Do you have Hodgkin's Lymphoma or Cutaneous T-Cell Lymphoma? Has your lymphoma come back, or has it not gotten better after your last treatment? If so, you might be able to take part in a study that will modify your own immune cells to see if it may treat your lymphoma.

Have you been diagnosed with a plasma cell disorder? You may be able to join a registry to help us learn more about the effects of plasma cell disorders on different aspects of life.

Have you been diagnosed with melanoma? If so, you may be eligible to take part in a research study looking at the safety of giving a combination of drugs called Ulixertinib and Palbociclib to patients with advanced melanoma.

The purpose of this study is to establish a safe dose of study cells to give to patients with relapsed/ refractory ALL expressing CD19.

Do you have bladder, kidney, prostate, or another genitourinary cancer diagnosis? If so, you may be able to take part in a research study collecting specimens (e.g., blood, urine, saliva, tissue) during your already scheduled appointments. Collecting these specimens may help researchers develop new ways to detect cancer earlier or to more effectively treat cancer.

The overall objective of this project is to examine differences in performance fatigability and contributing mechanisms between firefighters in cancer remission and healthy firefighter controls. Findings from this research project will inform future interventions to reduce CRF in firefighters in cancer remission.

To evaluate whether different biomarkers can stratify patients with newly diagnosed GBM that have progressive enhancement within 12 weeks post-XRT into risk groups based on overall survival.

To provide AMTAGVI per United States Prescribing Information (USPI) to patients.